- Previous Close
2.3600 - Open
2.3600 - Bid 2.1700 x 200
- Ask 2.3500 x 200
- Day's Range
2.2000 - 2.3600 - 52 Week Range
1.1800 - 3.7800 - Volume
81,544 - Avg. Volume
459,325 - Market Cap (intraday)
60.957M - Beta (5Y Monthly) 1.96
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2000 - Earnings Date Mar 10, 2025 - Mar 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.50
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
www.icadmed.comRecent News: ICAD
View MorePerformance Overview: ICAD
Trailing total returns as of 3/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ICAD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ICAD
View MoreValuation Measures
Market Cap
63.25M
Enterprise Value
44.87M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.28
Price/Book (mrq)
2.12
Enterprise Value/Revenue
2.31
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-14.29%
Return on Assets (ttm)
-8.95%
Return on Equity (ttm)
-17.56%
Revenue (ttm)
18.94M
Net Income Avi to Common (ttm)
-5.3M
Diluted EPS (ttm)
-0.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
18.79M
Total Debt/Equity (mrq)
1.41%
Levered Free Cash Flow (ttm)
-2.1M